Navigation Links
Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
Date:10/31/2011

Avastin®, an antibody that blocks the activity of VEGF-A, clinically validated anti-angiogenic drugs as an effective means of inhibiting solid tumour growth. By blocking the interaction of VEGF-A with its receptors, primarily VEGFR-2, the multi-billion dollar cancer therapeutic slows tumour growth by inhibiting blood vessel recruitment into the tumour, effectively starving tumours of essential nutrients and oxygen required for growth. However after a short period of time tumors can begin to grow again in the presence of Avastin® . Avastin® is approved by the US FDA in the following indications: metastatic colorectal cancer, non-squamous-cell lung cancer, metastatic breast cancer, glioblastoma, and metastatic renal cell carcinoma.

The angiogenic receptor VEGFR-2 can also be stimulated by VEGF-C and hence an inhibitor such as VGX-100, a key therapeutic in Circadian's portfolio, can produce greater blockade of this receptor pathway. As such, VGX-100 has the potential to block blood vessel growth in tumours which grow in the presence of Avastin® therapy and hence may completely shut down angiogenesis (the growth of blood vessels) mediated by VEGFR-2.

VEGF-C along with the molecule VEGF-D are also the only known proteins to bind and activate VEGFR-3 which drives lymphatic vessel and tumour-associated blood vessel growth. Inhibitors of VEGF-C thus have therapeutic potential to inhibit not only primary tumour growth through their anti-angiogenic activities, but to also inhibit tumour spread or metastasis via the lymphatic vessels - a mechanism of tumour dissemination that is often the deadliest aspect of many tumour types and a mechanism that is not effectively blocked by anti-VEGF-A or anti-VEGFR-2 therapeutics.

Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is desi
'/>"/>

SOURCE Circadian Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems
4. Mylan Receives Approval for Generic Version of MS Contin® Tablets
5. SAFC Verona HPAPI Manufacturing Facility Receives SafeBridge Certification
6. INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection
7. Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System
8. Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
9. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
10. Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
11. Institute of Health Sciences Receives ABHES Institutional Accreditation for Long Distance Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... ORLANDO, Fla. , Aug. 27, 2014 By ... Challenge, you,re likely not living on this planet. The awareness ... social consciousness and has helped to raise over $88.5 Million ... are getting involved and some companies are starting to as ... in Orlando, Florida , who actually works ...
(Date:8/27/2014)... Aug. 27, 2014 ISPE , the ... has released a preview of its Drug Shortages ... avoid drug shortages and maintain a robust and reliable ... The Plan, a first for the industry, was developed ... members and describes how industry can best prevent drug ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Heart Valve Repair ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart Valve Repair ... human heart which control the flow of blood ... heart valve diseases such as valvular stenosis, valvular ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 3ISPE Releases First Look at its Plan to Prevent Drug Shortages 4Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... 24 Schering-Plough Corporation (NYSE: SGP ... selective adenosine2a receptor antagonist, met the primary endpoint ... suffering from moderate to severe Parkinson,s disease experiencing ... The trial results were presented today at the ...
... , Dear President-Elect Obama:, , ... will start with billions of dollars,earmarked for stem cell research. ... is the voice of the Repair Stem Cell research and,treatment ... federal,funding support for our industry and the medical and scientific ...
Cached Medicine Technology:Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute 2
(Date:8/27/2014)... New York (PRWEB) August 27, 2014 ... by Transparency Market Research "Ablation Technologies Market (Applications: ... Radiofrequency, Light/Laser, Electrical, Ultrasound, Microwave, Cryotherapy) - Global ... 2014 - 2020," the global ablation technologies market ... and is estimated to reach a market worth ...
(Date:8/27/2014)... new analysis of clinical trial participation in the largest ... found participants are not representative of the larger patient ... Hospital cardiologist Dr. Jay Udell. The study authors call ... the wider population, and suggest the use of broader ... participation. , "We know that clinical trials can be ...
(Date:8/27/2014)... the onset of a cancer defense mechanism known ... Cancer Center are leveraging it in a new ... cell death rather than survival. The novel treatment ... referred to as the "Trash Man" due to ... autophagy. Results from preclinical experiments suggest this experimental ...
(Date:8/27/2014)... Disability (CLD) has received a two-year, $600,000 grant ... the Health Resources and Services Administration to support ... at improving services for children and youth with ... project, CLD worked with an Autism Advisory Council ... resulting plan addresses priorities of increased awareness of ...
(Date:8/27/2014)... (Lebanon, NH 8/27/14)Dartmouth cancer researchers developed and tested ... and environmental interactions that contribute to disease as ... , The approach fills a gap in ... from complex interactions among genetic and environmental factors. ... relevant interactions versus those that reflect chance combinations ...
Breaking Medicine News(10 mins):Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... colleagues from the Institute of Child Health will be studying ... The study will focus on the changes in their brain ... identify and understand the problems in their brain which could ... study is being funded by the Action Medical Research, UK. ...
... grow and currently affects more that 18 million ... need for alternative diabetes therapies with earlier more ... of insulin by the lung may provide an ... alternative insulin delivery systems must meet certain pharmacokinetic ...
... as the Breast Cancer Awareness Month. It is a sad ... and mortality associated with breast cancer//, very few men and ... risk factors and what is to be done in case ... Lauder, founder and president of the Breast Cancer Research Foundation, ...
... Los Angles have taken a major step forward in the ... the development of prostate cancer in animals//. ,The antibody ... and according to Dr. Robert E. Reiter, a professor of ... study's senior author it tells the cancer that it is ...
... known to express endogenous peptide antibiotics called defensins, ... active against bacteria, fungi and viruses//. ... of Nature, describes plectasin-the first defensin to be ... nigrella. Plectasin has primary, secondary and tertiary structures ...
... the deadly HIV/AIDS is accelerating in China with 126,808 ... patients, according to latest health reports//. Experts estimate that ... 80,000 AIDS patients. ,This is considerably higher than the ... over a margin of 19,818. In addition, the patients ...
Cached Medicine News:Health News:New Research To Study Brain Changes In Premature Births 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Mushroom found to be a source of a new antibiotic: Plectasin 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: